Is HELP or SPRY more profitable?

Cybin has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Cybin's return on equity of -59.98% beat ARS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -59.98% -50.80% ARS Pharmaceuticals -200.00% -153.61% -60.85%

Does the media favor HELP or SPRY?

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Cybin. MarketBeat recorded 10 mentions for ARS Pharmaceuticals and 6 mentions for Cybin. Cybin's average media sentiment score of 0.37 beat ARS Pharmaceuticals' score of 0.12 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, HELP or CRON?

Cronos Group has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$81.31M -$4.23 N/A Cronos Group $146.59M 7.06 -$9.45M $0.01 277.50

Is HELP or CRON more profitable?

Cybin has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. Cronos Group's return on equity of -1.26% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -59.98% -50.80% Cronos Group -1.14% -1.26% -1.20%

Does the media favor HELP or CRON?

In the previous week, Cybin had 3 more articles in the media than Cronos Group. MarketBeat recorded 6 mentions for Cybin and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.26 beat Cybin's score of 0.37 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, HELP or JBIO?

Jade Biosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$81.31M -$4.23 N/A Jade Biosciences N/A N/A -$127.41M -$2.02 N/A

Is HELP or JBIO more profitable?

Jade Biosciences' return on equity of -51.34% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -59.98% -50.80% Jade Biosciences N/A -51.34% -47.32%

Does the media prefer HELP or JBIO?

In the previous week, Cybin had 4 more articles in the media than Jade Biosciences. MarketBeat recorded 6 mentions for Cybin and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.93 beat Cybin's score of 0.37 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jade Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, HELP or BIOA?

BioAge Labs has higher revenue and earnings than Cybin. BioAge Labs is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$81.31M -$4.23 N/A BioAge Labs $10.32M 100.73 -$80.61M -$2.40 N/A

Is HELP or BIOA more profitable?

Cybin has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -59.98% -50.80% BioAge Labs -871.75% -29.40% -27.26%

Does the media prefer HELP or BIOA?

In the previous week, Cybin had 2 more articles in the media than BioAge Labs. MarketBeat recorded 6 mentions for Cybin and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.47 beat Cybin's score of 0.37 indicating that BioAge Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, HELP or SANA?

Sana Biotechnology is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$81.31M -$4.23 N/A Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A

Is HELP or SANA more profitable?

Cybin's return on equity of -59.98% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -59.98% -50.80% Sana Biotechnology N/A -108.01% -40.68%

Cybin (HELP) Competitors

$6.54 +0.52 (+8.57%)

As of 12:57 PM Eastern

Compare

HELP vs. SPRY, CRON, JBIO, BIOA, and SANA

Should you buy Cybin stock or one of its competitors? MarketBeat compares Cybin with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cybin include ARS Pharmaceuticals (SPRY), Cronos Group (CRON), Jade Biosciences (JBIO), BioAge Labs (BIOA), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.

How does Cybin compare to ARS Pharmaceuticals?

Cybin (NASDAQ:HELP) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Cybin has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Cybin has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Cybin's return on equity of -59.98% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Cybin. MarketBeat recorded 10 mentions for ARS Pharmaceuticals and 6 mentions for Cybin. Cybin's average media sentiment score of 0.37 beat ARS Pharmaceuticals' score of 0.12 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

17.9% of Cybin shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cybin currently has a consensus price target of $58.75, indicating a potential upside of 798.87%. ARS Pharmaceuticals has a consensus price target of $28.20, indicating a potential upside of 234.32%. Given Cybin's stronger consensus rating and higher possible upside, equities research analysts clearly believe Cybin is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cybin has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
ARS Pharmaceuticals	$84.28M	9.94	-$171.30M	-$2.01	N/A

Summary

Cybin beats ARS Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Cybin compare to Cronos Group?

Cybin (NASDAQ:HELP) and Cronos Group (NASDAQ:CRON) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

In the previous week, Cybin had 3 more articles in the media than Cronos Group. MarketBeat recorded 6 mentions for Cybin and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.26 beat Cybin's score of 0.37 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cronos Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cybin has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Cronos Group has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Cronos Group has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
Cronos Group	$146.59M	7.06	-$9.45M	$0.01	277.50

17.9% of Cybin shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 7.8% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cybin presently has a consensus target price of $58.75, suggesting a potential upside of 798.87%. Cronos Group has a consensus target price of $2.30, suggesting a potential downside of 17.12%. Given Cybin's stronger consensus rating and higher possible upside, research analysts plainly believe Cybin is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Cybin has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. Cronos Group's return on equity of -1.26% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
Cronos Group	-1.14%	-1.26%	-1.20%

Summary

Cronos Group beats Cybin on 8 of the 15 factors compared between the two stocks.

How does Cybin compare to Jade Biosciences?

Cybin (NASDAQ:HELP) and Jade Biosciences (NASDAQ:JBIO) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Cybin has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market.

Jade Biosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

In the previous week, Cybin had 4 more articles in the media than Jade Biosciences. MarketBeat recorded 6 mentions for Cybin and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.93 beat Cybin's score of 0.37 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jade Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

17.9% of Cybin shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Jade Biosciences' return on equity of -51.34% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
Jade Biosciences	N/A	-51.34%	-47.32%

Cybin currently has a consensus target price of $58.75, suggesting a potential upside of 798.87%. Jade Biosciences has a consensus target price of $47.13, suggesting a potential upside of 120.11%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

Jade Biosciences beats Cybin on 8 of the 14 factors compared between the two stocks.

How does Cybin compare to BioAge Labs?

Cybin (NASDAQ:HELP) and BioAge Labs (NASDAQ:BIOA) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Cybin had 2 more articles in the media than BioAge Labs. MarketBeat recorded 6 mentions for Cybin and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.47 beat Cybin's score of 0.37 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioAge Labs has higher revenue and earnings than Cybin. BioAge Labs is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
BioAge Labs	$10.32M	100.73	-$80.61M	-$2.40	N/A

Cybin has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

17.9% of Cybin shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 20.8% of BioAge Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cybin has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
BioAge Labs	-871.75%	-29.40%	-27.26%

Cybin presently has a consensus target price of $58.75, indicating a potential upside of 798.87%. BioAge Labs has a consensus target price of $43.50, indicating a potential upside of 86.10%. Given Cybin's stronger consensus rating and higher possible upside, equities analysts clearly believe Cybin is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

BioAge Labs beats Cybin on 9 of the 15 factors compared between the two stocks.

How does Cybin compare to Sana Biotechnology?

Cybin (NASDAQ:HELP) and Sana Biotechnology (NASDAQ:SANA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Sana Biotechnology is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

17.9% of Cybin shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cybin's return on equity of -59.98% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
Sana Biotechnology	N/A	-108.01%	-40.68%

Cybin has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

Cybin currently has a consensus price target of $58.75, suggesting a potential upside of 798.87%. Sana Biotechnology has a consensus price target of $9.50, suggesting a potential upside of 179.00%. Given Cybin's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cybin is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Cybin had 5 more articles in the media than Sana Biotechnology. MarketBeat recorded 6 mentions for Cybin and 1 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.87 beat Cybin's score of 0.37 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Cybin	Neutral
Sana Biotechnology	Very Positive

Summary

Sana Biotechnology beats Cybin on 7 of the 13 factors compared between the two stocks.

Get Cybin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HELP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HELP vs. The Competition

Export

Metric	Cybin	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$339.74M	$2.95B	$4.36B	$12.23B
Dividend Yield	N/A	15.31%	11.51%	5.90%
P/E Ratio	-1.56	13.53	22.02	24.11
Price / Sales	N/A	2,985.12	205.54	101.47
Price / Cash	N/A	26.03	38.01	53.91
Price / Book	0.83	4.89	13.62	6.36
Net Income	-$81.31M	-$34.85M	$115.37M	$337.58M
7 Day Performance	39.96%	-1.04%	-0.86%	-0.29%
1 Month Performance	47.54%	-1.46%	-2.29%	0.26%
1 Year Performance	N/A	12.30%	11.48%	26.83%

Cybin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HELP Cybin	2.7127 of 5 stars	$6.54 +8.6%	$58.75 +798.9%	N/A	$339.74M	N/A	N/A	50	News Coverage High Trading Volume
SPRY ARS Pharmaceuticals	3.4104 of 5 stars	$10.28 +3.0%	$28.60 +178.2%	-53.5%	$991.05M	$84.28M	N/A	90	News Coverage Analyst Forecast
CRON Cronos Group	1.3138 of 5 stars	$2.70 +1.9%	$2.30 -14.8%	+44.4%	$988.54M	$146.59M	270.27	450	Positive News
JBIO Jade Biosciences	2.8532 of 5 stars	$21.86 +12.4%	$47.13 +115.6%	+107.5%	$960.05M	N/A	N/A	20
BIOA BioAge Labs	2.5703 of 5 stars	$22.32 +4.0%	$43.50 +94.9%	N/A	$954.40M	$8.99M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HELP) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cybin (HELP) Competitors

HELP vs. SPRY, CRON, JBIO, BIOA, and SANA

How does Cybin compare to ARS Pharmaceuticals?

Summary

How does Cybin compare to Cronos Group?

Summary

How does Cybin compare to Jade Biosciences?

Summary

How does Cybin compare to BioAge Labs?

Summary

How does Cybin compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cybin (HELP) Competitors

HELP vs. SPRY, CRON, JBIO, BIOA, and SANA

How does Cybin compare to ARS Pharmaceuticals?

Which has more volatility and risk, HELP or SPRY?

Is HELP or SPRY more profitable?

Does the media favor HELP or SPRY?

Do institutionals and insiders have more ownership in HELP or SPRY?

Do analysts prefer HELP or SPRY?

Which has preferable earnings & valuation, HELP or SPRY?

Summary

How does Cybin compare to Cronos Group?

Does the media favor HELP or CRON?

Which has more volatility and risk, HELP or CRON?

Which has preferable valuation and earnings, HELP or CRON?

Do institutionals & insiders hold more shares of HELP or CRON?

Do analysts rate HELP or CRON?

Is HELP or CRON more profitable?

Summary

How does Cybin compare to Jade Biosciences?

Which has more volatility & risk, HELP or JBIO?

Which has stronger earnings and valuation, HELP or JBIO?

Does the media prefer HELP or JBIO?

Do insiders & institutionals hold more shares of HELP or JBIO?

Is HELP or JBIO more profitable?

Do analysts prefer HELP or JBIO?

Summary

How does Cybin compare to BioAge Labs?

Does the media prefer HELP or BIOA?

Which has higher valuation & earnings, HELP or BIOA?

Which has more volatility and risk, HELP or BIOA?

Do institutionals & insiders hold more shares of HELP or BIOA?

Is HELP or BIOA more profitable?

Do analysts recommend HELP or BIOA?

Summary

How does Cybin compare to Sana Biotechnology?

Which has preferable valuation & earnings, HELP or SANA?

Do institutionals & insiders hold more shares of HELP or SANA?

Is HELP or SANA more profitable?

Which has more risk & volatility, HELP or SANA?

Do analysts prefer HELP or SANA?

Does the media favor HELP or SANA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools